Login to Your Account

Genzyme Has Satisfying Quarter; Cerezyme Gives 'Upside Surprise'

By Randall Osborne

Friday, April 16, 2004
Genzyme Corp. reported first-quarter 2004 results that topped Wall Street's consensus, as company officials during a conference call took questions on legal challenges, patent-estate security and dosing of its enzyme-replacement therapy for Pompe disease. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription